We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The Eversense E3 CGM System uses a calibration algorithm that continuously assesses the sensor’s glucose sensitivity and based on this information, the system determines whether 1 or 2 calibrations/day are needed after day 21. This ensures the best possible system accuracy is maintained.
While it is possible, in the Eversense E3 pivotal clinical trial (PROMISE Study), most users were in 1 calibration/day 62% of the time and in 2 calibrations a day 38% of the time, after day 21.
The Eversense E3 CGM System uses a calibration algorithm that continuously assesses changes in the sensor’s glucose sensitivity. This sensitivity varies by individual, and from day to day. The need for 1 or 2 calibrations/day is determined by the system based on this continuous assessment, and there is no specific action a user can take to change the frequency of calibrations. However, providing the system with an accurate blood glucose value is important. Always calibrate the system using only a fingerstick blood sample. DO NOT calibrate at times when glucose may be rapidly changing (e.g., after meals, after dosing insulin). DO NOT use an alternative site (such as forearm or palm) blood glucose reading to calibrate the system.
The system will always prompt for the number of calibrations per day needed to maintain best system accuracy for each individual user. There is nothing wrong with the system if 2 calibrations/day are needed.
The Eversense E3 CGM System uses a calibration algorithm that continuously assesses changes in the sensor’s glucose sensitivity. This sensitivity varies by individual, and from day to day. The need for 1 or 2 calibrations/day is determined by the system based on this continuous assessment, and there is no specific action a user can take to change the frequency of calibrations.
A compatible smart device is required in order to use the Eversense E3 CGM. Please see our Compatibility page for a list of compatible devices.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060